APOA5

APOA5
Identifiers
Aliases	APOA5, APOAV, RAP3, apolipoprotein A5
External IDs	OMIM: 606368; MGI: 1913363; HomoloGene: 14197; GeneCards: APOA5; OMA:APOA5 - orthologs
Gene location (Human)
Chr.	Chromosome 11 (human)
End	116,792,420 bp
Gene location (Mouse)
Chr.	Chromosome 9 (mouse)
End	46,183,217 bp
RNA expression pattern
	Top expressed in
	right lobe of liver; ; body of pancreas; ; gonad; ; intestinal epithelium; ; urinary system; ; blood; ; wall of uterus; ; hippocampal formation; ; kidney; ; myometrium;
	Top expressed in
	left lobe of liver; ; gallbladder; ; yolk sac; ; sexually immature organism; ; embryo; ; embryo; ; Ileal epithelium; ; medial head of gastrocnemius muscle; ; cingulate gyrus; ; thoracic diaphragm;
	More reference expression data
	n/a
Gene ontology
Molecular function	heparin binding; lipoprotein particle receptor binding; phosphatidylcholine binding; lipoprotein lipase activator activity; lipase binding; lipase activator activity; low-density lipoprotein particle receptor binding; cholesterol binding; enzyme binding; enzyme activator activity; phosphatidylcholine-sterol O-acyltransferase activator activity; phospholipid binding; cholesterol transfer activity; lipid binding;
Cellular component	blood microparticle; chylomicron; very-low-density lipoprotein particle; extracellular region; low-density lipoprotein particle; high-density lipoprotein particle; extracellular space; endoplasmic reticulum lumen;
Biological process	neuron projection regeneration; positive regulation of receptor-mediated endocytosis; lipid transport; positive regulation of triglyceride catabolic process; tissue regeneration; positive regulation of cholesterol esterification; phospholipid efflux; positive regulation of lipid catabolic process; positive regulation of lipoprotein lipase activity; high-density lipoprotein particle assembly; positive regulation of fatty acid biosynthetic process; triglyceride catabolic process; regulation of intestinal cholesterol absorption; cholesterol efflux; cholesterol biosynthetic process; cholesterol homeostasis; acylglycerol homeostasis; positive regulation of very-low-density lipoprotein particle remodeling; phosphatidylcholine metabolic process; triglyceride metabolic process; triglyceride-rich lipoprotein particle remodeling; triglyceride homeostasis; reverse cholesterol transport; regulation of lipid metabolic process; lipoprotein metabolic process; post-translational protein modification; regulation of cholesterol transport; very-low-density lipoprotein particle remodeling; positive regulation of lipid biosynthetic process;
	Sources:Amigo / QuickGO
Orthologs
	116519
	66113
	ENSG00000110243
	ENSMUSG00000032079
	Q6Q788
	Q8C7G5
	NM_052968; NM_001166598; NM_001371904
	NM_080434; NM_001348095
	NP_001160070; NP_443200; NP_001358833
	NP_536682; NP_001335024
	Wikidata
View/Edit Human	View/Edit Mouse

Apolipoprotein A-V is a protein that in humans is encoded by the APOA5 gene on chromosome 11.^[5]^[6]^[7] It is significantly expressed in liver.^[8] The protein encoded by this gene is an apolipoprotein and an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of several lipoprotein fractions including VLDL, HDL, chylomicrons. It is believed that apoA-V affects lipoprotein metabolism by interacting with LDL-R gene family receptors.^[9] Considering its association with lipoprotein levels, APOA5 is implicated in metabolic syndrome.^[10] The APOA5 gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.^[11]

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000110243 – Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000032079 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. (October 2001). "An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing". Science. 294 (5540). New York, N.Y.: 169–173. Bibcode:2001Sci...294..169P. doi:10.1126/science.1064852. OSTI 789171. PMID 11588264. S2CID 42251337.
^ van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. (November 2001). "Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration". The Journal of Biological Chemistry. 276 (48): 44512–44520. doi:10.1074/jbc.M106888200. PMID 11577099.
^ "Entrez Gene: APOA5 apolipoprotein A-V".
^ "BioGPS - your Gene Portal System". biogps.org. Retrieved 2016-10-11.
^ Nilsson SK, Christensen S, Raarup MK, Ryan RO, Nielsen MS, Olivecrona G (September 2008). "Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families". The Journal of Biological Chemistry. 283 (38): 25920–25927. doi:10.1074/jbc.M802721200. PMC 2533778. PMID 18603531.
^ Xu C, Bai R, Zhang D, Li Z, Zhu H, Lai M, et al. (2013-01-01). "Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis". PLOS ONE. 8 (2): e56216. Bibcode:2013PLoSO...856216X. doi:10.1371/journal.pone.0056216. PMC 3585417. PMID 23468858.
^ Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. (June 2015). "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials". Lancet. 385 (9984). London, England: 2264–2271. doi:10.1016/S0140-6736(14)61730-X. PMC 4608367. PMID 25748612.

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000110243 – Ensembl, May 2017

[refGRCm38Ensembl-2] GRCm38: Ensembl release 89: ENSMUSG00000032079 – Ensembl, May 2017

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[Pennacchio_2001-5] Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. (October 2001). "An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing". Science. 294 (5540). New York, N.Y.: 169–173. Bibcode:2001Sci...294..169P. doi:10.1126/science.1064852. OSTI 789171. PMID 11588264. S2CID 42251337.

[van_der_Vliet_2001-6] van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. (November 2001). "Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration". The Journal of Biological Chemistry. 276 (48): 44512–44520. doi:10.1074/jbc.M106888200. PMID 11577099.

[entrez_116519-7] "Entrez Gene: APOA5 apolipoprotein A-V".

[8] "BioGPS - your Gene Portal System". biogps.org. Retrieved 2016-10-11.

[Nilsson_2008-9] Nilsson SK, Christensen S, Raarup MK, Ryan RO, Nielsen MS, Olivecrona G (September 2008). "Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families". The Journal of Biological Chemistry. 283 (38): 25920–25927. doi:10.1074/jbc.M802721200. PMC 2533778. PMID 18603531.

[Xu_2013-10] Xu C, Bai R, Zhang D, Li Z, Zhu H, Lai M, et al. (2013-01-01). "Effects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis". PLOS ONE. 8 (2): e56216. Bibcode:2013PLoSO...856216X. doi:10.1371/journal.pone.0056216. PMC 3585417. PMID 23468858.

[Mega_2015-11] Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. (June 2015). "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials". Lancet. 385 (9984). London, England: 2264–2271. doi:10.1016/S0140-6736(14)61730-X. PMC 4608367. PMID 25748612.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]